Who are LingZhi capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comarum Palustre, herbal immunomodulator, Lamivudine+Oxymatrine Capsules, Umckamin syrup, Dendrobium Huoshanense Suppository, A. Paniculata and A. Chilensis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lingzhi-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

LingZhi capsule — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LingZhi capsule (LingZhi capsule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal immunomodulator. Area: Oncology.

phase 3 Herbal immunomodulator Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LingZhi capsule (LingZhi capsule) — The University of Hong Kong. LingZhi capsule is a traditional Chinese medicine-derived immunomodulatory agent that enhances immune function and promotes anti-tumor activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LingZhi capsule TARGET	LingZhi capsule	The University of Hong Kong	phase 3	Herbal immunomodulator
Comarum Palustre	Comarum Palustre	Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology	marketed	herbal immunomodulator
herbal immunomodulator	herbal immunomodulator	Tatyasaheb Kore Dental College	marketed	Herbal immunomodulator
Lamivudine+Oxymatrine Capsules	Lamivudine+Oxymatrine Capsules	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor + herbal immunomodulator	Reverse transcriptase; oxymatrine targets multiple immune pathways (non-specific)
Umckamin syrup	Umckamin syrup	Korea United Pharm. Inc.	phase 3	Herbal immunomodulator
Dendrobium Huoshanense Suppository	Dendrobium Huoshanense Suppository	Zhejiang Cancer Hospital	phase 3	Herbal immunomodulator
A. Paniculata and A. Chilensis	A. Paniculata and A. Chilensis	Vedic Lifesciences Pvt. Ltd.	phase 3	Herbal immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal immunomodulator class)

Korea United Pharm. Inc. · 1 drug in this class
Tatyasaheb Kore Dental College · 1 drug in this class
The University of Hong Kong · 1 drug in this class
Vedic Lifesciences Pvt. Ltd. · 1 drug in this class
Zhejiang Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LingZhi capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/lingzhi-capsule. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing